{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:39:49Z","timestamp":1792636789121,"version":"4.5.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100024516","name":"Astellas Pharma Deutschland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024516","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006044","name":"Astellas Pharma Europe Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006044","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.clgc.2024.102278","type":"journal-article","created":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T11:34:20Z","timestamp":1732275260000},"page":"102278","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Real-world Evidence for Enfortumab Vedotin in Patients with Metastatic Urothelial Cancer: An Austrian Multicentre Study"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0544-5773","authenticated-orcid":false,"given":"Dora","family":"Niedersuess-Beke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Mayrhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2825-3442","authenticated-orcid":false,"given":"Johanna","family":"Krauter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Schnabel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3966-1071","authenticated-orcid":false,"given":"Simon Peter","family":"Gampenrieder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Miechowiecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7396-9494","authenticated-orcid":false,"given":"David","family":"Kiesl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7806-4819","authenticated-orcid":false,"given":"Ferdinand","family":"Luger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4672-2028","authenticated-orcid":false,"given":"Jakob","family":"Pfuner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5921-2807","authenticated-orcid":false,"given":"Clemens","family":"Wiesinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0146-8089","authenticated-orcid":false,"given":"Sonia","family":"Vallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haleh","family":"Andalibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Vais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Banner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz","family":"Stoiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmin","family":"Spielgelberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Barth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bauernhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Aufderklamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9904-1720","authenticated-orcid":false,"given":"Sabine","family":"Weibrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"M\u00fchlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Hilbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3392-9046","authenticated-orcid":false,"given":"Florence","family":"Boulm\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Klinglmair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Heintel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Pichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5286-9048","authenticated-orcid":false,"given":"Renate","family":"Pichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2024.102278_bib0001","series-title":"StatPearls.","article-title":"Bladder Cancer","author":"Kaseb","year":"2024"},{"issue":"3","key":"10.1016\/j.clgc.2024.102278_bib0002","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clgc.2024.102278_bib0003","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211047352","article-title":"Metastatic Urothelial cancer: a rapidly changing treatment landscape","volume":"13","author":"Stecca","year":"2021","journal-title":"Ther Adv Med Oncol"},{"issue":"10","key":"10.1016\/j.clgc.2024.102278_bib0004","doi-asserted-by":"crossref","first-page":"7587","DOI":"10.3390\/curroncol29100599","article-title":"Understanding treatment patterns and outcomes among patients with De Novo unresectable locally advanced or metastatic urothelial cancer: a population-level retrospective analysis from Alberta, Canada","volume":"29","author":"Alimohamed","year":"2022","journal-title":"Curr Oncol."},{"issue":"3","key":"10.1016\/j.clgc.2024.102278_bib0005","doi-asserted-by":"crossref","first-page":"e618","DOI":"10.1016\/j.clgc.2019.03.009","article-title":"PD-1\/PD-L1 combinations in advanced urothelial cancer: rationale and current clinical trials","volume":"17","author":"Hsu","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2024.102278_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.122910","article-title":"Nectin-4-directed antibody-drug conjugates (ADCs): spotlight on preclinical and clinical evidence","volume":"352","author":"Khosravanian","year":"2024","journal-title":"Life Sci."},{"issue":"12","key":"10.1016\/j.clgc.2024.102278_bib0007","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab Vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"issue":"29","key":"10.1016\/j.clgc.2024.102278_bib0008","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1200\/JCO.19.01140","article-title":"Pivotal trial of Enfortumab Vedotin in urothelial carcinoma after platinum and anti-programmed death 1\/programmed death ligand 1 therapy","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2024.102278_bib0009","first-page":"27","article-title":"The evolving therapeutic landscape and role of enfortumab vedotin in advanced urothelial carcinoma: a systematic review","volume":"19","author":"Talukder","year":"2023","journal-title":"Oncol Haematol"},{"issue":"2","key":"10.1016\/j.clgc.2024.102278_bib0010","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3390\/jmahp12020009","article-title":"Real-world evidence to reinforce clinical trial evidence in health technology assessment: a critical review of Real-world evidence requirements from seven countries and recommendations to improve acceptance","volume":"12","author":"Thokagevistk","year":"2024","journal-title":"J Mark Access Health Policy"},{"issue":"11","key":"10.1016\/j.clgc.2024.102278_bib0011","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.annonc.2023.08.016","article-title":"EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma","volume":"34","author":"Rosenberg","year":"2023","journal-title":"Ann Oncol."},{"issue":"4","key":"10.1016\/j.clgc.2024.102278_bib0012","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.euo.2020.01.001","article-title":"Synchronous versus metachronous Metastatic disease: impact of time to metastasis on patient outcome-results from the International Metastatic Renal Cell Carcinoma Database Consortium","volume":"3","author":"Donskov","year":"2020","journal-title":"Eur Urol Oncol."},{"issue":"11","key":"10.1016\/j.clgc.2024.102278_bib0013","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1111\/iju.15542","article-title":"Outcomes and prognostic factors in patients with synchronous and metachronous oligometastatic urothelial carcinoma with visceral metastases","volume":"31","author":"Yoshida","year":"2024","journal-title":"Int J Urol."},{"issue":"6","key":"10.1016\/j.clgc.2024.102278_bib0014","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/cncr.34057","article-title":"Efficacy of enfortumab vedotin in advanced urothelial cancer: analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study","volume":"128","author":"Koshkin","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2024.102278_bib0015","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.euros.2023.04.018","article-title":"Enfortumab Vedotin in metastatic urothelial carcinoma: survival and safety in a European multicenter real-world patient cohort","volume":"53","author":"Zsch\u00e4bitz","year":"2023","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.clgc.2024.102278_bib0016","series-title":"presented at: ASCO GU","article-title":"Safety and efficacy of enfortumab vedotin in patients with metastatic\/locally advanced urothelial cancer: real-world evidence from a European database","author":"Zsch\u00e4bitz","year":"2024"},{"issue":"4","key":"10.1016\/j.clgc.2024.102278_bib0017","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/iju.15368","article-title":"Real world evidence of enfortumab vedotin in patients with advanced urothelial cancer: a multicenter observational study","volume":"31","author":"Fukuokaya","year":"2024","journal-title":"Int J Urol"},{"issue":"9","key":"10.1016\/j.clgc.2024.102278_bib0018","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.21873\/anticanres.16594","article-title":"Efficacy and tolerability of Enfortumab Vedotin for metastatic urothelial carcinoma: early experience in the real world","volume":"43","author":"Minato","year":"2023","journal-title":"Anticancer Res."},{"issue":"3","key":"10.1016\/j.clgc.2024.102278_bib0019","doi-asserted-by":"crossref","first-page":"e223","DOI":"10.1093\/oncolo\/oyac001","article-title":"Management of dermatologic events associated with the Nectin-4-directed antibody-drug conjugate Enfortumab Vedotin","volume":"27","author":"Lacouture","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.clgc.2024.102278_bib0020","series-title":"presented at: ASCO","article-title":"Impact of exposures on outcomes with enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer","author":"Petrylak","year":"2024"},{"issue":"20","key":"10.1016\/j.clgc.2024.102278_bib0021","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1200\/JCO.23.01983","article-title":"NECTIN4 Amplification is frequent in solid tumors and predicts Enfortumab Vedotin response in metastatic urothelial cancer","volume":"42","author":"Kl\u00fcmper","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324002489?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324002489?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T15:21:41Z","timestamp":1753111301000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767324002489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S1558767324002489"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102278","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world Evidence for Enfortumab Vedotin in Patients with Metastatic Urothelial Cancer: An Austrian Multicentre Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102278","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102278"}}